The Global Chronic Idiopathic Constipation CIC Drugs Market size is expected to grow at a CAGR of 5.1% during the forecast period (2021-2028). The growth of this market is driven by the rising number of patients suffering from chronic idiopathic constipation, increasing healthcare expenditure, and technological advancements in the field. However, high costs and lack of awareness about the disease are some factors that may hinder its growth over the next few years.
Chronic Idiopathic Constipation CIC Drugs can be defined as the drugs which are used to treat chronic idiopathic constipation (CIC). These types of drugs can be classified into two categories: The first category includes the prokinetic agents, such as lubiprostone and linaclotide. The second one is comprised of laxatives that do not act on their own but work in a synergistic manner with other treatments or therapies for constipation. This type may include psyllium husk powder, polyethylene glycol-sodium hydroxide solution, docusate sodium, or milk of magnesia.
CIC drugs are used to treat chronic idiopathic constipation, a condition that causes hard stools and infrequent bowel movements. CIC treatments range from lifestyle changes such as eating high-fiber foods to medications such as lubiprostone (Amitiza), linaclotide (Constella), or Miralax.
On the basis of Type, the market is segmented into Lubiprostone, Linaclotide, and Others.
Lubiprostone is a prescription medication that slows down the movement of food through your intestines. This helps to reduce stomach pain and constipation symptoms such as hard stools, little or no bowel movements, straining while passing stool (tenesmus), and abdominal bloating. Lubiprostone also reduces urgency in people with both chronic idiopathic constipation and irritable bowel syndrome with constipation for 12 weeks or more who are not responding adequately to laxatives alone.
The drug is used by adults who have chronic idiopathic constipation lasting at least three months but less than five years; children under 18 should only be given lubiprostone if it's been determined they're suffering from chronic idiopathic constipation and their stomach is empty.
Linaclotide is the first approved drug for chronic idiopathic constipation. It works by increasing intestinal muscle contractions and fluid secretion in order to ease bowel movements. The treatment only needs to be taken once a day, as opposed to three times a day with lubiprostone or daily with prunes/prune juice which is also a treatment for CICs. This makes Linaclotide much easier than other options on the market that require more time commitment from patients (alongside their doctors).
On the basis of Application, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centres, and Long Term Care Centres. The hospital segment accounted for about 40% share in 2017 and this percentage is projected to go up due to the increasing population requiring medical attention (thus leading them into health care facilities) as well as raising awareness among people regarding treatment options available for chronic idiopathic constipation. The growing geriatric population also contributes significantly towards the growth of CIC drug usage at these centers where they are treated on regular basis either through outpatient or inpatient services.
On the basis of Region, the market is segmented into North America, Latin America, Europe, and the Asia Pacific. The North American market is expected to have a bigger revenue share in the global market. The U.S is the major country with a predominantly population and high awareness of chronic constipation which provides an opportunity for CIC drug development.
The Latin American countries are forecasted to grow at a rapid pace due to the increasing aging population, growth in healthcare expenditure, low incidence rates, and strong economic outlooks in these regions.
Asia Pacific region has shown robust growth over the past few years as it contributes significantly towards the world’s GDP on account of its fast-growing economies such as China and India; increased number of gastroenterologists coupled with rising disposable income can be accounted for this phenomenon.
In Europe, Germany accounts for the majority share followed by France because both these nations offer high-quality healthcare services.
The Middle East and Africa regions are forecasted to grow at a moderate pace due to their limited access to healthcare facilities, low disposable incomes of the population in these countries, and availability of generic drugs for CIC treatment.
Up Market Research published a new report titled “Chronic Idiopathic Constipation CIC Drugs Market research report which is segmented by Types (Lubiprostone, Linaclotide, Others), By Applications (Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others), By Players/Companies Actavis, Chugai Pharmaceutical, Ferring International Center, Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding, Sanofi, Bayer, Salix Pharmaceuticals, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Progenics Pharmaceuticals”.
|Report Attributes||Report Details|
|Report Title||Chronic Idiopathic Constipation CIC Drugs Market Research Report|
|By Type||Lubiprostone, Linaclotide, Others|
|By Application||Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others|
|By Companies||Actavis, Chugai Pharmaceutical, Ferring International Center, Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding, Sanofi, Bayer, Salix Pharmaceuticals, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Progenics Pharmaceuticals|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||208|
|Number of Tables & Figures||146|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type Lubiprostone, Linaclotide, Others and By Application Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others.
Some of the companies that are profiled in this report are:
Chronic Idiopathic Constipation CIC Drugs Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Chronic Idiopathic Constipation CIC Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Chronic Idiopathic Constipation CIC Drugs Market Report:
Some other reports from this category!